

September 9 (THU)

September 10 (FRI)

09:00-09:10

Opening Ceremony

### Symposium 1

09:10 - 11:10

Public health response to COVID-19

Chair :

S1-1

Public health response to COVID-19: National perspective  
Hsien-Ho Lin ( National Taiwan University ), Chinese Taipei

S1-2

Public health response to COVID-19: Regional perspective  
Sharon Salmon ( WHO WPRO ), Singapore

S1-3

Public health response to COVID-19: Global perspective  
Maria Van Kerkhove ( WHO ), Switzerland

S1-4

Strategies to flatten the curve: current evidence and practical pitfalls  
Paul Tambyah ( National University Hospital ), Singapore

### Symposium 2

09:10 - 11:10

Gram-negative bacteria

Chair :

S2-1

Epidemiology and impact of carbapenem-resistant Acinetobacter and Pseudomonas  
Po-Ren Hsueh ( National Taiwan University Hospital ), Chinese Taipei

S2-2

Epidemiology and impact of carbapenem-resistant Enterobacteriaceae  
Anucha Apisarntharak ( Thammasat University Hospital ), Thailand

S2-3

Emergence of intrinsically resistant gram-negative bacteria:  
Stenotrophomonas, Burkholderia, and Chryseobacterium  
José Luis Martínez ( Centro Nacional de Biotecnología. CSIC ), Spain

S2-4

Antimicrobial therapy for carbapenem-resistant gram-negative bacteria  
Yohei Doi ( University of Pittsburgh ), USA

### Symposium 3

09:10 - 11:10

How I treat difficult-to-treat infections (interactive)

Chair :

S3-1

How I treat persistent S. aureus bacteremia  
Vance Fowler ( Duke Department of Medicine ), USA

S3-2

How I treat vascular graft infections  
Alexia Anagnostopoulos ( University Hospital Zurich ), Switzerland

S3-3

How I treat CMV infection in high-risk pediatric patients?  
YaeJean Kim ( Samsung Medical Center ), Korea

### Plenary Lecture 1

11:10 - 11:50

Chair :

P-1

Pandemic preparedness: are we ready for the future?  
Michael T. Osterholm ( University of Minnesota ), USA

### Plenary Lecture 2

11:50 - 12:30

Chair :

P-2

Vaccines against SARS-CoV-2  
Jerome H. Kim ( International Vaccine Institute )

Korea

### Plenary Lecture 3

15:10 - 15:50

Chair :

p-3 Overview of the current status of antimicrobial resistance  
David Livermore ( University of East Anglia )

UK

### Symposium 4

15:50 - 17:20 Clinical management of COVID-19

Chair :

S4-1 Therapeutic options for COVID-19  
Davey Smith ( University of California San Diego ), USA

S4-2 Critical care of patients with severe COVID-19  
Yaseen M. Arabi ( King Abdullah International Medical Research Center ), Saudi Arabia

S4-3 Long-term sequelae of COVID-19  
Bin Cao ( National Clinical Research Center for Respiratory Diseases ), PR China

### Symposium 5

15:50 - 17:20 Diagnostics/clinical microbiology

Chair :

S5-1 The future is here: rapid diagnosis of antimicrobial resistance  
Robin Patel ( Mayo Clinic ), USA

S5-2 Next-generation sequencing for diagnosing infectious diseases  
John W. A. Rossen ( Department of Medical Microbiology and Infection Prevention, University of Groningen ), The Netherlands

S5-3 How to combine novel techniques with stewardship: a real-world experience  
Tristan Timbrook, PharmD ( bioMérieux; The University of Utah ), USA

### Symposium 6

15:50 - 17:20 Antimicrobial stewardship

Chair :

S6-1 Shorter the better: current evidence for the shorter duration of antibiotic therapy  
Brad Spellberg ( University of Southern California ), USA

S6-2 Incentives for antimicrobial stewardship: situation in Asia  
David Lye ( Tan Tock Seng Hospital ), Singapore

S6-3 Antimicrobial stewardship during the COVID-19 pandemic  
Timothy M. Rawson ( Imperial College London ), UK

September 10 (FRI)

### Symposium 7

09:00 - 11:00 Pros and cons (interactive) Chair :

S7-1 Early oral transition for endocarditis  
Pro) Brad Spellberg ( University of Southern California Medical Center ), USA /  
Con) Vance Fowler ( Duke Department of Medicine ), USA

S7-2 Piperacillin-tazobactam for ESBL-producing Enterobacterales  
Pro) Jesús Rodríguez-Baño ( Universidad de Sevilla ), Spain / Con) Patrick  
Harris ( The University of Queensland ), Australia

S7-3 Combination regimen for carbapenem-resistant Acinetobacter infections  
Pro) Andrea L. Kwa ( Singapore General Hospital ), Singapore / Con) Visanu  
Thamlikitkul ( Mahidol University), Thailand

### Symposium 8

09:00 - 11:00 Gram-positive bacteria Chair :

S8-1 Update on antimicrobial resistance of Staphylococcus  
Michael Otto ( National Institute of Allergy and Infectious Diseases ), USA

S8-2 Antimicrobial resistance and treatment options for enterococcal infections  
Benjamin P. Howden ( University of Melbourne ), Australia

S8-3 How to dose vancomycin: time to go Bayesian?  
Michael Rybak ( Wayne State University ), USA

S8-4 Novel therapeutic approaches to bacterial infection  
Andrew M. Edwards ( Imperial College London ), UK

### Symposium 9

09:00 - 11:00 Infection prevention and control Chair :

S9-1 Airborne, droplet, or something in between: physics of respiratory secretions  
Qian Hua ( South East University in Nanjing ), PR China

S9-2 Infection control for COVID-19: theory and practice  
Kalisvar Marimuthu ( National Centre for Infectious Diseases ), Singapore

S9-3 Environmental cleaning & disinfection: current controversies  
Stephan Harbarth ( Geneva University Hospital ), Switzerland

S9-4 Outbreak control in healthcare settings  
Doo Ryeon Chung ( Samsung Medical Center ), Korea

### Plenary Lecture 4

11:10 - 11:50 Chair :

P-4 The Trifecta of Diagnostic Stewardship, Antimicrobial  
Stewardship, and Value Assessment of New Diagnostic Tests  
Robin Patel ( Mayo Clinic ), USA

### Plenary Lecture 5

11:50 - 12:30 Chair :

P-5 Promoting the development of novel therapeutic agents  
Dennis M. Dixon ( National Institute of Allergy and Infectious Diseases ), USA

### Plenary Lecture 6

15:10 - 15:50

Chair :

P-6

Designing and conducting clinical trials that change the practice  
David Paterson ( University of Queensland ), Australia

### Symposium 10

15:50 - 17:20

Fungus

Chair :

S10-1

Epidemiology and impact of anti-fungal resistance in Asia  
Ban Hock Tan ( Singapore General Hospital ), Singapore

S10-2

The confluence between viral and fungal infections  
Monica Slavin ( The University of Melbourne ), Australia

S10-3

Novel therapeutic options for invasive fungal infections  
David W. Denning ( The University of Manchester and Global Action Fund for Fungal Infections ), UK

### Symposium 11

15:50 - 17:20

Vaccine

Chair :

S11-1

Future role of vaccines on antibacterial resistance  
Rino Rappuoli ( GSK Vaccines ), Italy

S11-2

Novel technologies for vaccine development  
Kaitlyn M. Morabito ( DMID, NIAID, NIH ), USA

S11-3

What we learned from COVID-19 vaccination  
Eui-Cheol Shin ( Korea Advanced Institute of Science and Technology ), Korea

### Symposium 12

15:50 - 17:20

HIV

Chair :

S12-1

Aging and non-communicable diseases in people living with HIV  
Peter Reiss ( University of Amsterdam ), The Netherlands

S12-2

Diagnosis and Treatment of HIV with Complex Drug-Resistance  
Roy M. Gulick ( Weill Cornell Medicine ), USA

S12-3

Disparities in PrEP access in the Asia Pacific  
Shui Shan Lee ( The Chinese University of Hong Kong ), Hong Kong, China

## Registration

ISAAR 2021 조직위원회는 국내 참가자에게는 공식 등록비와 달리 별도 참가비 혜택을 드리고 있으며, 올해는 특히 **참가비 30% 특별 할인**이 제공되니, 조기 등록으로 더욱 더 많은 혜택을 받으시기 바랍니다!

	<b>사전등록</b> (~2021년 8월 13일)	<b>현장등록</b> (2021년 8월 14일~)
일반참가자	20만원 → <b>14만원</b>	30만원 → <b>20만원</b>
전공의*	10만원 → <b>7만원</b>	15만원 → <b>10만원</b>
학부생**	<b>무료</b>	<b>무료</b>

\* 학부생을 제외한 군의관, 공보의, 간호사, 병리사 모두를 포함 / \*\* 학생의 경우 학생증 제출 필수

 @vISAAR2021  @ISAAR2021  showcase/isaar

For any inquiries, please contact to: **ISAAR 2021 Secretariat**

Suite 1712, Rosedale Officetel, 280 Gwangpyeong-ro, Gangnam-gu, Seoul, 06367, Korea  
Tel: +82-2-3413-0327 / Fax: +82-2-6258-0327 / Email: isaar@apfid.org

**APFID** ASIA PACIFIC FOUNDATION  
FOR INFECTIOUS DISEASES